Vabicaserin has been used in trials studying the health services research and treatment of Schizophrenia.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | Vabicaserin may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Vabicaserin. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Vabicaserin. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Vabicaserin. |
| Hydrocodone | Vabicaserin may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Vabicaserin. |
| Magnesium sulfate | The therapeutic efficacy of Vabicaserin can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Vabicaserin may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Vabicaserin may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Vabicaserin. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Vabicaserin. |
| Orphenadrine | Vabicaserin may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Vabicaserin may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Vabicaserin. |
| Pramipexole | Vabicaserin may increase the sedative activities of Pramipexole. |
| Ropinirole | Vabicaserin may increase the sedative activities of Ropinirole. |
| Rotigotine | Vabicaserin may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Vabicaserin. |
| Sodium oxybate | Vabicaserin may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | Vabicaserin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Vabicaserin. |
| Thalidomide | Vabicaserin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Vabicaserin may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Vabicaserin. |
| Linezolid | The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Vabicaserin. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Vabicaserin is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Vabicaserin is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Vabicaserin is combined with (S)-Warfarin. |
| Mirtazapine | Vabicaserin may increase the serotonergic activities of Mirtazapine. |
| Ethanol | Vabicaserin may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Vabicaserin may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Vabicaserin. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Nefazodone. |
| Zimelidine | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with Vabicaserin. |
| Seproxetine | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Seproxetine. |
| Levomilnacipran | The risk or severity of serotonin syndrome can be increased when Vabicaserin is combined with Levomilnacipran. |
| Indalpine | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Alaproclate. |
| Methylene blue | Vabicaserin may increase the serotonergic activities of Methylene blue. |
| Zopiclone | The risk or severity of adverse effects can be increased when Vabicaserin is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Vabicaserin. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Vabicaserin. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with Vabicaserin. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of Vabicaserin. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with Vabicaserin. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Vabicaserin. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with Vabicaserin. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with Vabicaserin. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with Vabicaserin. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with Vabicaserin. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with Vabicaserin. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with Vabicaserin. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with Vabicaserin. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with Vabicaserin. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with Vabicaserin. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with Vabicaserin. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with Vabicaserin. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with Vabicaserin. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with Vabicaserin. |
| Venlafaxine | The risk or severity of serotonin syndrome can be increased when Vabicaserin is combined with Venlafaxine. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with Vabicaserin. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with Vabicaserin. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with Vabicaserin. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with Vabicaserin. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with Vabicaserin. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Vabicaserin. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with Vabicaserin. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Vabicaserin. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with Vabicaserin. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with Vabicaserin. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with Vabicaserin. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with Vabicaserin. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with Vabicaserin. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with Vabicaserin. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with Vabicaserin. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Vabicaserin. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Vabicaserin. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with Vabicaserin. |
| Meprobamate | The risk or severity of CNS depression can be increased when Meprobamate is combined with Vabicaserin. |